ALT Altimmune Inc

Altimmune to Announce Year End 2019 Financial Results on March 27

Altimmune to Announce Year End 2019 Financial Results on March 27

GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.

Conference Call Details
Date:Friday, March 27
Time:8:30 am Eastern Time
Domestic:877-423-9813
International:201-689-8573
Conference ID:13701071
Webcast:

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit .             

Contacts: 
Will BrownAshley R. Robinson
Chief Financial OfficerLifeSci Advisors, LLC
Phone: 240-654-1450617-430-7577
EN
25/03/2020

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Present at Upcoming EASL International Liver Congress™ 20...

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index (MASHResInd; Loomba 2024), a highly sensitive non-invasive measure of MASH histologic response, in a poster session at ...

19h / 41m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in the Citizens Life Sciences Conference

Altimmune to Participate in the Citizens Life Sciences Conference GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows: Conference:Citizens Life Sciences ConferenceDate/Time:Wednesday, May 7, 2025, at 9:30 a.m. EDT   The session will be webcast and can be accessed by visiting the section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage...

April 30, 2025 1 EN
Free Trial
ALT ALTIMMUNE INC

Altimmune Inc: 1 director

A director at Altimmune Inc maiden bought 10,000 shares at 5.200USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

03/15/25 March 15, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Host Virtual R&D Day on March 13, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025 Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering t...

March 6, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in the Leerink Global Healthcare Conference

Altimmune to Participate in the Leerink Global Healthcare Conference GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows: Conference:Leerink Global Healthcare Conference  Date/Time:Monday, March 10, 2025, at 3:40 p.m. EST The session will be webcast and can be accessed by visiting the section of the Altimmune website. About Altimmune Altimmune is a late cli...

March 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch